Vivet Therapeutics, participated by Ysios Capital and Columbus Venture, closes an exclusive license option with Mirum Pharmaceuticals
13/04/2021 Press release MIRUM PHARMACEUTICALS AND VIVET THERAPEUTICS ENTER INTO EXCLUSIVE WORLDWIDE OPTION AND LICENSE AGREEMENT FOR VIVET’S GENE THERAPY PROGRAMS TARGETING PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS. – Mirum expands potential opportunities across rare disease pipeline – Vivet to lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2…